LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Saunders-Pullman, Rachel; Barrett, Matthew J; Stanley, Kaili M; Luciano, Marta San; Shanker, Vicki; Severt, Lawrence; Hunt, Ann; Raymond, Deborah; Ozelius, Laurie J; Bressman, Susan B

Saunders-Pullman, Rachel; Barrett, Matthew J; Stanley, Kaili M; Luciano, Marta San; Shanker, Vicki; Severt, Lawrence; Hunt, Ann; Raymond, Deborah; Ozelius, Laurie J; Bressman, Susan B.

Affiliation

Saunders-Pullman R; Department of Neurology, Beth Israel Medical Center, New York, New York, USA. rsaunder@bethisraelny.org

Mov Disord ; 25(15): 2536-41, 2010 Nov 15.

Article in En | MEDLINE | ID: mdl-20818610

Subject(s)

Mutation; Neoplasms/genetics; Parkinson Disease/genetics; Protein Serine-Threonine Kinases/genetics; Risk; Age of Onset; Aged; Aged, 80 and over; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Jews/genetics; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Logistic Models; Male; Middle Aged; Neoplasms/complications; Parkinson Disease/complications; Statistics, Nonparametric

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Parkinson Disease / Risk / Protein Serine-Threonine Kinases / Mutation / Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Mov Disord Year: 2010 Document type: Article

Fulltext

XML

PubMed Links

Search on Google